Proactive Investors - Run By Investors For Investors

ReNeuron jumps at opening bell as it gets green light to begin second part of phase I/II eye disease trial

Data from the phase II part of the phase I/II trial is expected in the second half of 2018, with readouts from the subsequent, larger phase IIb study due in 2020
ReNeuron will use the new formulation of its hRPC therapy in the phase II trial

The ongoing phase I/II trial of ReNeuron Group Plc’s (LON:RENE) human retinal progenitor cell (hRPC) therapy has been given the green light by regulators to move into the phase II part of the study.

The hRPC therapy candidate is being trialled in patients with retinitis pigmentosa – a rare degenerative eye disease which can lead to blindness.

READ: ReNeuron making good progress with all of its key therapeutic programmes

The Data Safety Monitoring board gave its approval following short-term data from the nine patients taking part in the study, which indicated the therapy was safe and well-tolerated at the three doses tested.

ReNeuron has been hard at work developing a new formulation of hRPC recently which can be cryopreserved (frozen), extending its shelf life and allowing it to be shipped anywhere around the globe.

Cryopreserved formulation to be used in phase II trial

The final high-dose cohort patients in the phase I part of the study was treated with this new formulation, and the company expects to this version in the phase II element of the study.

This part of the trial will recruit six patients whose diseases haven’t progressed as much as those in the phase I element.

Readouts from the phase II trial are expected in the second half of next year, with efficacy data from a subsequent, larger phase IIb study due in 2020.

ReNeuron confirmed once again that an application will also be filed later this year to test the same hRPC therapy in a phase II trial in cone-rod dystrophy patients, and it hopes to have both phase II trials (RP and CRD) running concurrently.

‘High commercial potential’

"We are delighted that the Data Safety Monitoring Board has given its approval to progress our ongoing clinical trial in retinitis pigmentosa into its Phase II element,” said chief executive Olav Hellebø.

“Our hRPC cell therapy candidate offers the potential for an entirely new therapeutic option for patients suffering from diseases of the retina such as retinitis pigmentosa and cone-rod dystrophy, and represents a therapeutic platform technology with high commercial potential for ReNeuron.”

Shares rose 7.3% to 2.05p at the opening bell on Wednesday.

View full RENE profile View Profile

ReNeuron Group PLC Timeline

December 19 2018

Related Articles

knee physio
Results from an eight-year clinical extension study showed that ChondroMimetic was able to regenerate cartilage to a structural quality almost identical to native cartilage
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use